163 related articles for article (PubMed ID: 35474660)
1. Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patients.
Miyoshi Y; Yasui M; Ttsutsumi S; Kawahara T; Uemura KI; Hayashi N; Nozawa M; Yoshimura K; Uemura H; Uemura H
BJUI Compass; 2021 Jan; 2(1):31-38. PubMed ID: 35474660
[TBL] [Abstract][Full Text] [Related]
2. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
[TBL] [Abstract][Full Text] [Related]
3. Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
Kobayashi T; Terada N; Kimura T; Matsubara N; Murakami K; Mori K; Fujimoto Y; Akamatsu S; Inoue T; Ogawa O
Clin Genitourin Cancer; 2020 Feb; 18(1):e46-e54. PubMed ID: 31759831
[TBL] [Abstract][Full Text] [Related]
4. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.
Oh WK; Cheng WY; Miao R; Vekeman F; Gauthier-Loiselle M; Duh MS; Drea E; Szatrowski TP
Urol Oncol; 2018 Nov; 36(11):500.e1-500.e9. PubMed ID: 30201382
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
[TBL] [Abstract][Full Text] [Related]
6. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
de Wit R; Wülfing C; Castellano D; Kramer G; Eymard JC; Sternberg CN; Fizazi K; Tombal B; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Bono J
ESMO Open; 2021 Oct; 6(5):100241. PubMed ID: 34450475
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2017 Dec; 15(6):e1073-e1080. PubMed ID: 28826931
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
Onal C; Kose F; Ozyigit G; Aksoy S; Oymak E; Muallaoglu S; Guler OC; Tilki B; Hurmuz P; Akyol F
Prostate; 2021 Jun; 81(9):543-552. PubMed ID: 33905131
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy.
Fujiwara M; Fujiwara R; Oguchi T; Komai Y; Numao N; Yamamoto S; Yonese J; Yuasa T
Anticancer Res; 2022 Apr; 42(4):2123-2130. PubMed ID: 35347036
[TBL] [Abstract][Full Text] [Related]
10. Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.
Kuppen MCP; Westgeest HM; van den Eertwegh AJM; van Moorselaar RJA; van Oort IM; Coenen JLLM; van den Bergh ACMF; Mehra N; Somford DM; Bergman AM; Ten Bokkel Huinink D; Fossion L; Geenen MM; Hendriks MP; van de Luijtgaarden ACM; Polee MB; Weijl NI; van de Wouw AJ; de Wit R; Uyl-de Groot CA; Gerritsen WR
Eur Urol Oncol; 2021 Aug; 4(4):618-627. PubMed ID: 31601523
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study.
Matsumoto T; Hori Y; Shiota M; Blas L; Nakamura M; Seki N; Kuroiwa K; Yokomizo A; Morokuma F; Kiyoshima K; Eto M
Int J Urol; 2023 Feb; 30(2):139-146. PubMed ID: 36305673
[TBL] [Abstract][Full Text] [Related]
12. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Shore N; Higano CS; George DJ; Sternberg CN; Saad F; Tombal B; Miller K; Kalinovsky J; Jiao X; Tangirala K; Sartor O
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):680-688. PubMed ID: 32404868
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Androgen Receptor-targeted Drugs After Prostate Cancer Recurrence With Bone Metastases: PROSTAT-BSI Sub-analysis.
Kamijima T; Yaegashi H; Mizokami A; Nakajima K; Matsuyama H; Ichikawa T; Nishimoto K; Takahashi S; Shiina H; Horikoshi H; Hashine K; Sugiyama Y; Miyao T; Kamiyama M; Harada K; Ito A; Enokida H
Anticancer Res; 2022 Jun; 42(6):3099-3108. PubMed ID: 35641302
[TBL] [Abstract][Full Text] [Related]
14. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Kim SI; Szeto AH; Morgan KP; Brower B; Dunn MW; Khandani AH; Godley PA; Rose TL; Basch EM; Milowsky MI; Whang YE; Crona DJ
PLoS One; 2021; 16(6):e0253021. PubMed ID: 34153052
[TBL] [Abstract][Full Text] [Related]
15. Radium-223 (Xofigo) with concurrent abiraterone or enzalutamide: predictive biomarkers of improved overall survival in a clinically advanced cohort.
Rathbun JT; Franklin GE
Curr Probl Cancer; 2019 Jun; 43(3):205-212. PubMed ID: 29983206
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate.
Miyoshi Y; Uemura K; Kawahara T; Yoneyama S; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Yao M; Uemura H
Clin Genitourin Cancer; 2017 Aug; 15(4):472-478. PubMed ID: 28110835
[TBL] [Abstract][Full Text] [Related]
17. Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer -5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life.
Jiang XY; Atkinson S; Pearson R; Leaning D; Cumming S; Burns A; Azzabi A; Frew J; McMenemin R; Pedley ID
Clin Oncol (R Coll Radiol); 2020 Oct; 32(10):e177-e187. PubMed ID: 32448724
[TBL] [Abstract][Full Text] [Related]
18. Radium-223 in the Third-Line Setting in Metastatic Castration-Resistant Prostate Cancer: Impact of Concomitant Use of Enzalutamide on Overall Survival (OS) and Predictors of Improved OS.
Ahmed ME; Joshi VB; Badawy M; Pagliaro LC; Karnes RJ; Lowe V; Thorpe MP; Kwon ED; Kendi AT
Clin Genitourin Cancer; 2021 Jun; 19(3):223-229. PubMed ID: 33632570
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]